2008 May;24(5):1435-42. doi: 10.1185/030079908x301848.

The most common reason to discontinue Alphagan is redness, irritation, burning eyes and eyelids. Name must be less than 100 characters I certify that I am a U.S. healthcare professional.© 2020 Allergan.

This occurs in about 8% of patients taking the medication for long periods of time.

Menu. 2014 Feb;111(2):107-12. doi: 10.1007/s00347-013-2931-x.Saudi J Ophthalmol.

Simbrinza ia an effective two medicine combination that is used when one medication alone is not effective, and you are looking for ease of using both medications in one drop. Curr Med Res Opin. All trademarks are the property of their respective owners. Clipboard, Search History, and several other advanced features are temporarily unavailable. Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. This site needs JavaScript to work properly. One of the unique differences between the older Alphagan and the newer Alphagan-P was the elimination of its preservative, benzalkonium chloride. The tolerability of brimonidine tartrate 0.15%--referred to as bromonidine-Purite 0.15% in this study--was compared with brimonidine tartrate 0.2% in irritated eyes of healthy volunteers as well as patients with glaucoma or ocular hypertension (N=20) in a 2-week, single-center, randomized, double-ma … Visit The information provided in this website is intended for U.S. healthcare professionals only. 2012 Nov;109(11):1077-81. doi: 10.1007/s00347-012-2639-3.Rhee DJ, Peace JH, Mallick S, Landry TA, Bergamini MV; Study Group.Clin Ophthalmol. Alphagan-P (bromonidine) is used to treat open angle glaucoma and I have several hundred patients that have used it 2 or 3 times per day with no long term side effects. Following CAE exposure at visit 1, 70.6% of the participants preferred brimonidine-Purite 0.15% over brimonidine tartrate 0.2% and indicated that it was significantly more comfortable than brimonidine tartrate 0.2% (P=.009). You can still use this website if you do not click “Accept,” but your experience may be different.

Unable to load your delegates due to an error They continued to administer the drug bilaterally twice daily until day 15, when the preferred medication was again compared with the previous regimen.

ALPHAGAN ® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.. 2 DOSAGE AND ADMINISTRATION.

Unable to load your collection due to an error By clicking “Accept” you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above.
1996 Nov;41 Suppl 1:S19-26. Allergan Inc. has introduced a new Alphagan P (brimonidine tartrate ophthalmic solution) 0.1%, a reformulation of Alphagan 0.2% and Alphagan P 0.15%.

On day 11, the treatment was crossed over, and participants were asked to compare the preferred medication with their previous regimen. 2011 Oct;25(4):389-94. doi: 10.1016/j.sjopt.2011.08.004. ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
When given brimonidine tartrate 0.2% first before switching to brimonidine-Purite 0.15%, 85% preferred brimonidine-Purite 0.15% (P=.001).

From day 7 to 10, participants administered either drug bilaterally.

The results of this study suggest that brimonidine-Purite 0.15% is significantly more comfortable than brimonidine tartrate 0.2% in patients with irritated eyes. Alphagan-P, as we now know, ultimately replaced Allergan’s previous product, Alphagan (0.2% brimonidine tartrate).

Participants who reported a sufficient level of bilateral ocular discomfort during exposure to the CAE were enrolled in this study and received 1 drop of brimonidine-Purite 0.15% in 1 eye and 1 drop of brimonidine tartrate 0.2% in the contralateral eye. At day 0, they were exposed to a controlled adverse environment (CAE), in which humidity, temperature, and airflow was regulated, for up to 90 minutes. 2002 Apr;11(2):119-26. doi: 10.1097/00061198-200204000-00007.Curr Med Res Opin.